HEV vaccine trial results published in Lancet
Hepatitis E virus (HEV) infection is prevalent around the world, especially affecting low-income countries in Asia and Africa. High morbidity and mortality have been reported in pregnant women and their children. The only licensed vaccine against HEV, the recombinant HEV239, has been used in a large RCT in Bangladesh. The results from the clinical trial were published in Lancet recently. Senior author is Susanne G. Dudman, head of the The Clinical Virology Research Group group at the Department of Microbiology.